Abstract
Moxonidine is an imidazoline compound which acts on I1 imidazoline ‘receptors’ in the central nervous system to reduce blood pressure. This novel mechanism of action is claimed to lead to fewer adverse effects than the older centrally-acting agents such as clonidine. In this review we examine the drug’s pharmacology, clinical pharmacokinetics, efficacy as an antihypertensive agent including comparative studies with pre-existing drugs, and adverse effect profile. With a growing number of effective antihypertensive agents already available to the clinician, it is not yet clear whether moxonidine represents a significant advance in hypertension management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morris, S., Reid, J. Moxonidine: a review. J Hum Hypertens 11, 629–635 (1997). https://doi.org/10.1038/sj.jhh.1000518
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000518
Keywords
This article is cited by
-
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions
Signal Transduction and Targeted Therapy (2023)
-
Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions
Medicinal Chemistry Research (2016)
-
Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers
Psychopharmacology (2005)
-
The role of the central nervous system in hypertension
Current Hypertension Reports (1999)
